Information on ALPSIA
Basic details
Name: Autoimmune lymphoproliferative syndrome, type IA | Acronym: ALPSIA
Alt. names:
Gene: FAS | MOI: Autosomal recessive | Mechanism of action:
No. of cases in DB: 0 | First reported in: 1995
Last updated on: 2023-02-28 16:41:18 by
Description
It is characterized by splenomegaly, adenopathies, autoimmune cytopenias, increased lymphoma risk, IgG and A normal or increased, elevated serum FasL, IL-10, and vitamin B12. Patients show increased TCR +CD4-CD8-double negative (DN) T cells, and normal number of B cells, but low memory B cells
Management
Lymphoproliferation can be suppressed with medications such as corticosteroids, cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil; BMT/HSCT the only curative treatment for ALPS, has to date mostly been reported in patients with severe clinical findings; Surveillance for manifestations of lymphoproliferation and autoimmunity, and specialized imaging studies to detect malignant transformation may be beneficial .
Please mind that full curation of this condition has not started yet. Please contact us if you want to volunteer.
0 reported cases added to GenIA
SubjectID | Sex | Fam.ID | AD | AFM | Validity | Country | Population | Reference & Pub.code |
---|
AD: Age at genetic diagnosis; AFM: age at first manifestation; PMID: PubMed ID; GRID: GenIA reference ID (ref. not in PubMed).
Summary of clinical findings
[Considering only Definitive and Possible cases]
Rank | Clinical term | Present | Absent | Unreported |
---|
Please mind that full curation of this condition has not started yet. Please contact us if you want to volunteer.
Summary of treatment outcomes
[Considering only Definitive and Possible cases]
Treatment ⓘ | Responses & clinical indications |
---|
Please mind that full curation of this condition has not started yet. Please contact us if you want to volunteer.